Literature DB >> 20334851

Rethinking the concepts of community-acquired and health-care-associated pneumonia.

Santiago Ewig1, Tobias Welte, Jean Chastre, Antoni Torres.   

Abstract

The increasing numbers of patients who are elderly and severely disabled has led to the introduction of a new category of pneumonia management: health-care-associated pneumonia (HCAP). An analysis of the available evidence in support of this category, however, reveals heterogeneous and misleading definitions of HCAP, reliance on microbiological data of questionable validity, failure to recognise the contribution of aspiration pneumonia, failure to control microbial patterns for functional status, and failure to recognise frequently applied restrictions of treatment escalation as bias in assessing outcomes. As a result, the concept of HCAP contributes to confusion more than it provides a guide to pneumonia management, and it potentially leads to overtreatment. We suggest a reassignment of the criteria for HCAP to reconstruct the triad of community-acquired pneumonia (with a recognised core group of elderly and disabled patients and a subgroup of younger patients), hospital-acquired pneumonia, and pneumonia in immunosuppressed patients. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20334851     DOI: 10.1016/S1473-3099(10)70032-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  53 in total

1.  Healthcare-associated pneumonia: where do we go next?

Authors:  Marcos I Restrepo; Stefano Aliberti
Journal:  Clin Infect Dis       Date:  2013-11-22       Impact factor: 9.079

2.  Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.

Authors:  Elena Laserna; Oriol Sibila; Juan Felipe Fernandez; Diego Jose Maselli; Eric M Mortensen; Antonio Anzueto; Grant Waterer; Marcos I Restrepo
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

3.  Modern Management of Community-Acquired Pneumonia: Is It Cost-Effective and are Outcomes Acceptable?

Authors:  Dominik Mertz; Jennie Johnstone
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

Review 4.  Update in pulmonary infections 2010.

Authors:  Richard G Wunderink; Grant W Waterer
Journal:  Am J Respir Crit Care Med       Date:  2011-07-15       Impact factor: 21.405

5.  Emerging problems regarding severity assessment and treatment strategies for patients with pneumonia: controversies surrounding the HCAP concept.

Authors:  Yuichiro Shindo; Yoshinori Hasegawa
Journal:  Intern Emerg Med       Date:  2011-05-18       Impact factor: 3.397

Review 6.  Management of community-acquired pneumonia in older adults.

Authors:  Antonella F Simonetti; Diego Viasus; Carolina Garcia-Vidal; Jordi Carratalà
Journal:  Ther Adv Infect Dis       Date:  2014-02

7.  Community-Acquired Pneumonia in Adults.

Authors:  Martin Kolditz; Santiago Ewig
Journal:  Dtsch Arztebl Int       Date:  2017-12-08       Impact factor: 5.594

8.  Guideline-based antibiotics and mortality in healthcare-associated pneumonia.

Authors:  Karl J Madaras-Kelly; Richard E Remington; Kevin L Sloan; Vincent S Fan
Journal:  J Gen Intern Med       Date:  2012-03-07       Impact factor: 5.128

9.  A Composite of Functional Status and Pneumonia Severity Index Improves the Prediction of Pneumonia Mortality in Older Patients.

Authors:  Francisco Sanz; María Morales-Suárez-Varela; Estrella Fernández; Luis Force; María José Pérez-Lozano; Vicente Martín; Mikel Egurrola; Jesús Castilla; Jenaro Astray; Diana Toledo; Ángela Domínguez
Journal:  J Gen Intern Med       Date:  2018-01-04       Impact factor: 5.128

10.  Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.

Authors:  Russell T Attridge; Christopher R Frei; Mary Jo V Pugh; Kenneth A Lawson; Laurajo Ryan; Antonio Anzueto; Mark L Metersky; Marcos I Restrepo; Eric M Mortensen
Journal:  J Crit Care       Date:  2016-08-11       Impact factor: 3.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.